Nxera Pharma Co., Ltd.
4565.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.45 | -0.04 | 0.62 | 0.08 |
| FCF Yield | -3.44% | -0.33% | 0.62% | -11.81% |
| EV / EBITDA | -68.81 | 143.70 | -136.94 | -82.47 |
| Quality | ||||
| ROIC | -1.39% | -1.04% | -0.63% | -0.67% |
| Gross Margin | 60.42% | 78.01% | 75.69% | 68.96% |
| Cash Conversion Ratio | 1.78 | 0.08 | -0.81 | 8.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 32.27% | 26.94% | 26.10% | 22.81% |
| Free Cash Flow Growth | -1,040.00% | -153.57% | 104.53% | -856.67% |
| Safety | ||||
| Net Debt / EBITDA | -19.20 | 40.31 | -38.54 | -22.64 |
| Interest Coverage | -17.10 | -0.75 | -9.96 | -8.25 |
| Efficiency | ||||
| Inventory Turnover | 0.28 | 0.21 | 0.18 | 0.24 |
| Cash Conversion Cycle | 287.72 | 301.08 | 344.31 | 290.45 |